Sanjay Muttineni

Sourced from institutional research profiles (UAMS TRI or ARA).

Assistant Professor

UAMS

COM | Internal Med Hem-Onc

2 pubs

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Sanjay Muttineni's research focuses on the clinical outcomes and risk factors associated with cytomegalovirus reactivation in patients undergoing treatment for multiple myeloma. His work also investigates the prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy for relapsed or refractory multiple myeloma. He has examined long-term outcomes for multiple myeloma patients achieving minimal residual disease negativity and analyzed real-world data on cytokine release syndrome and immune effector cell-associated neurotoxicity following specific therapies for small cell lung cancer. Additionally, his research includes an assessment of infectious complications and intravenous immunoglobulin utilization in multiple myeloma patients treated with teclistamab. His scholarship includes two publications.

Metrics

Publications: 2

Selected Publications

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Blood Cancer Journal DOI OpenAlex
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 -6 . (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)

Blood DOI OpenAlex
Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation (2025)

Cureus DOI OpenAlex